Influenza: dealing with a continually emerging disease
DOI:
https://doi.org/10.33321/cdi.1996.20.27Abstract
There are two major types of influenza virus, types A and B, which are responsible for disease in man. Both types of virus display a progressive antigenic change known as antigenic drift while influenza A occasionally undergoes a more dramatic change known as antigenic shift. Antigenic shifts are typically associated with pandemic spread and severe disease and it is now believed that they occur when a new virus strain evolves by genetic reassortment between avian and human influenza viruses. In recent years influenza surveillance has provided for a good antigenic match between vaccines and the circulating epidemic viruses and the development of safe vaccines with good protective efficacy have been possible. However, in a pandemic situation the spread of the new virus is much more rapid and may well outstrip the capacity to produce vaccines.
Downloads
References
Payne AM-M. The influenza programme of WHO. Bull World Health Organ 1953; 8:755-774.
Parvin JD, Mascona A, Pan WT, et al. Measurement of the mutation rates of animal viruses: Influenza A virus and poliovirus type 1. J Virol 1986; 59:377-383.
Webster RG, Bean WJ, Gorman OT, et al. Evolution and ecology of influenza A viruses. Microbiol Rev 1992; 56:152-179.
Webster RG. Personal communication.
Kilbourne ED. Future influenza vaccines and the use of genetic recombinants. Bull World Health Organ 1969; 41:643-645.
Shortridge KF. Pandemic influenza: a zoonosis? Semin Respir Infect 1992; 7:11-25.
Scholtissek C. Molecular aspects of the epidemiology of virus disease. Experentia 1987; 43:1197-1201.
The new A/New Jersey/76 influenza strain (Memorandum). Bull World Health Organ 1976; 53:1-5.
Claas ECJ, Kawaoka Y, De Jong JC, et al. Infection of children with avian-human influenza virus from pigs in Europe. Virology 1994; 204:453-457.
Scholtissek C, Von Hoyningen V, Rott R. Genetic relatedness between the new 1977 epidemic strains (H1N1) of influenza and human influenza strains isolated between 1947 and 1957. Virology 1978; 89:613-617.
Lui KJ, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987; 77:712-716.
Sprenger MJW, Mulder PGH, Beyer WEP, et al. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989. Int J Epidemiol 1993; 22:334-340.
Carrat F, Valleron AJ. Influenza mortality among the elderly in France, 1980-90: how many deaths may have been avoided through vaccination? J Epidemiol Comm Health 1995; 49:419-425.
Schoenbaum SC. Economic impact of influenza. The individual’s perspective. Am J Med 1987; 82 (suppl 6A):26-30.
Tannock GA. Alternatives in the Control of Influenza. Med J Aust 1991; 154:692-695.
Strassburg MA, Greenland S, Sorvillo FJ, et al. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986; 4:38-44.
Gross PA, Ennis FA. Influenza vaccine: split-product versus whole-virus types - How do they differ? N Engl J Med 1977; 296:567-568.
Govaert TM, Dinant GJ, Aretz K, et al. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ 1993; 307:988-990.
Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518-527.
Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331:778-784.
Russell LB. Opportunity costs in modern medicine. Health Aff 1992; 11:162-169.
Scott WG, Scott HM. Economic evaluation of vaccination against influenza in New Zealand. Pharmacoeconomics 1996; 9:51-60.
Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333:889-893.
Channock RM, Murphy BR, Collins PL et al. Live viral vaccines for respiratory and enteric tract diseases. Vaccine 1988; 6:129-133.
Webster RG, Fynan EF, Santoro JC, Robinson HTI.Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin. Vaccine 1994; 12:1495 -1498
von Itzstein M, Wu W-Y, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363:418-423.
Downloads
Published
How to Cite
License
Copyright (c) 2023 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
